Multiple routes of drug administration and HIV risk among injecting drug users

Journal of Substance Abuse Treatment

Volumn 42, Issue 4, 2012, Pages 413-420

  Vorobjov, Sigrid ^a,b   Uusküla, Anneli ^b,c   Des Jarlais, Don C ^d   Abel Ollo, Katri ^a   Talu, Ave ^a   Rüütel, Kristi ^a  

^a NATIONAL INSTITUTE FOR HEALTH DEVELOPMENT   (Estonia)

^b UNIVERSITY OF TARTU   (Estonia)

^c UNIVERSITY OF TARTU   (Estonia)

^d BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

HIV; Illicit drug use; Injecting drug use; Risk behavior; Sexual risk behaviors

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; BUPRENORPHINE; CANNABIS; COCAINE; DIAMORPHINE; EPHEDRINE; FENTANYL; ILLICIT DRUG; METHADONE; PSEUDOEPHEDRINE;

ADULT; ARTICLE; DISEASE ASSOCIATION; DRUG ADMINISTRATION ROUTE; DRUG USE; ESTONIA; FEMALE; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROLOGY; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; VIRUS TRANSMISSION;

ADULT; CONFIDENCE INTERVALS; ESTONIA; FEMALE; FOCUS GROUPS; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; MALE; OVERDOSE; RISK; RISK FACTORS; SEXUALLY TRANSMITTED DISEASES; SMOKING; SOCIOECONOMIC FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; UNSAFE SEX;

EID: 84860387562     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2011.09.014     Document Type: Article

References (34)

1. Abel-Ollo K., Rahu M., Rajaleid K., Talu A., Rüütel K., Platt L., et al. Knowledge of HIV serostatus and risk behaviour among injecting drug users in Estonia. AIDS Care 2009, 21:851-857.
2. Celentano D.D., Latimore A.D., Mehta S.H. Variations in sexual risks in drug users: Emerging themes in a behavioral context. Current HIV/AIDS Reports 2008, 5:212-218.
3. Cohen M.S., Chen Y.Q., McCauley M., Gamble T., Hosseinipour M.C., Kumarasamy N., et al. Prevention of HIV-1 infection with early antiretroviral therapy. New England Journal of Medicine 2011, 365:493-505.
4. DeBeck K., Kerr T., Li K., Fischer B., Buxton J., Montaner J., et al. Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs. Canadian Medical Association Journal 2009, 81:585-589.
5. Des Jarlais D.C., Perlis T.E., Stimson G.V., Poznyak V. Using standardized methods for research on HIV and injecting drug use in developing/transitional countries: Case study from the WHO Drug Injection Study Phase II. BMC Public Health 2006, 6:54. WHO Phase II Drug Injection Collaborative Study Group.
6. Des Jarlais D.C., Arasteh K., Perlis T., Hagan H., Heckathorn D.D., McKnight C., et al. The transition from injection to non-injection drug use: Long-term outcomes among heroin and cocaine users in New York City. Addiction 2007, 102:778-785.
7. Des Jarlais, D. C., Hagan, H., Arasteh, K., McKnight, C., Semaan, S., & Perlman D. C. (In press). Can intranasal drug use reduce HCV infection among injecting drug users? Drug and Alcohol Dependence 2011 Jul 26. [Epub ahead of print].
8. Estonian Monitoring Centre for Drugs National report on drug situation in Estonia 2009 2010, National Institute for Health Development, Tallinn.
9. Fischer B., Rehm J., Blitz-Miller T. Injection drug use and preventive measures: A comparison of Canadian and western European jurisdictions over time. Canadian Medical Association Journal 2000, 162:1709-1713.
10. French M.T., McCollister K.E., Alexandre P.K., Chitwood D.D., McCoy C.B. Revolving roles in drug-related crime: The cost of chronic drug users as victims and perpetrators. Journal of Quantitative Criminology 2004, 20:217-241.
11. Green T.C., Heimer R., Grau L.E. Distinguishing signs of opioid overdose and indication for naloxone: An evaluation of six overdose training and naloxone distribution programs in the United States. Addiction 2008, 103:979-989.
12. Heckathorn D.D. Respondent-driven sampling: A new approach to the study of hidden populations. Social Problems 1997, 44:174-199.
13. Heckathorn D.D. Respondent-driven sampling II: Deriving valid population estimates from chain-referral samples of hidden populations. Social Problems 2002, 49:11-34.
14. Heckathorn D.D., Semaan S., Broadhead R.S., Hughes J.J. Extensions of respondent-driven sampling: A new approach to the study of injection drug users aged 18-25. AIDS and Behavior 2002, 6:55-67.
15. Lloyd-Smith E., Wood E., Li K., Montaner J.S., Kerr T. Incidence and determinants of initiation into cocaine injection and correlates of frequent cocaine injectors. Drug and Alcohol Dependence 2009, 99:176-182.
16. Lõhmus L., Abel-Ollo K., Loit H.M., Talu A., Uusküla A. HIV-nakkuse ning teiste infektsioonide ja riskikäitumise levimus süstivate narkomaanide seas Tallinnas ja Kohtla-Järvel. [Prevalence of HIV and other infections and risk behaviour among injecting drug users in Tallinn and Kohtla-Järve] Retrieved 20nd December 2010 from. http://www2.tai.ee/TAI/SN_RDS_uurimuse_raport_2007_17.12.2008.pdf.
17. Malekinejad M., Johnston L.G., Kendall C., Kerr L.R., Rifkin M.R., Rutherford G.W. Using respondent-driven sampling methodology for HIV biological and behavioral surveillance in international settings: A systematic review. AIDS and Behavior 2008, 12:S105-S130.
18. Platt L., Bobrova N., Rhodes T., Uusküla A., Parry J.V., Rüütel K., et al. High HIV prevalence of HIV among injecting drug users in Estonia: Implication for understanding the risk environment. AIDS 2006, 20:2103-2120.
19. Salganik M.J., Heckathorn D.D. Sampling and estimation in hidden populations using respondent-driven sampling. Sociological Methodology 2004, 34:193-239.
20. Semple S.J., Strathdee S.A., Zians J., Patterson T.L. Social and behavioral characteristics of HIV-positive MSM who trade sex for methamphetamine. American Journal of Drug and Alcohol Abuse 2010, 36:325-331.
21. Southwell M. Transitions to and from injecting. Injecting illicit drugs 2005, 118-134. Blackwell Publishing Ltd, Oxford. R. Pates, A. McBride, K. Arnold (Eds.).
22. Strathdee S.A., Stockman J.K. Epidemiology of HIV among injecting and non-injecting drug users: Current trends and implications for interventions. Current HIV/AIDS Reports 2010, 7:99-106.
23. Strang J., Bearn J., Farrell M., Finch E., Gossop M., Griffiths P., et al. Route of drug use and its implications for drug effect, risk of dependence and health consequences. Drug and Alcohol Review 1998, 17:197-211.
24. Talu A., Rajaleid K., Abel-Ollo K., Rüütel K., Rahu M., Rhodes T., et al. HIV infection and risk behaviour of primary fentanyl and amphetamine injectors in Tallinn, Estonia: Implications for intervention. The International Journal on Drug Policy 2010, 21:56-63.
25. Thorstensson R., Andersson S., Lindbäck S., Dias F., Mhalu F., Gaines H., et al. Evaluation of 14 commercial HIV-1/HIV-2 antibody assays using serum panels of different geographical origin and clinical stage including a unique seroconversion panel. Journal of Virological Methods 1998, 70:139-151.
26. UNAIDS/WHO Country profile for Estonia Retrieved 1st March 2010 from. http://www.unaids.org/en/CountryResponses/Countries/estonia.asp.
27. Uusküla A., Rajaleid K., Talu A., Abel K., Rüütel K., Hay G. Estimating injection drug use prevalence using state wide administrative data sources: Estonia 2004. Addiction Research and Theory 2007, 15:411-424.
28. Uusküla A., McNutt L.A., Dehovitz J., Fischer K., Heimer R. High prevalence of blood-borne virus infections and high-risk behaviour among injecting drug users in Tallinn. Estonia. International Journal of STD & AIDS 2007, 18:41-46.
29. Uusküla A., Kals M., Rajaleid K., Abel K., Talu A., Rüütel K., et al. High-prevalence and high-estimated incidence of HIV infection among new injecting drug users in Estonia: Need for large scale prevention programs. Journal of Public Health (Oxford, England) 2008, 30:119-125.
30. Volz E., Degani I., Heckathorn D.D. Respondent-Driven Sampling Analysis Tool (RDSAT) Version 5.6. Ithaca, NY: Cornell University Retrieved 20nd November 2009 from. http://www.respondentdrivensampling.org/.
31. Vorobjov S., Uusküla A., Abel-Ollo K., Talu A., Rüütel K., Des Jarlais D.C. Comparison of injecting drug users who obtain syringes from pharmacies and syringe exchange programs in Tallinn. Estonia. Harm Reduction Journal 2009, 20(6):3.
32. Weber B. Multicenter evaluation of the new automated Enzymun-Test Anti-HIV 1 + 2 + subtyp O. Journal of Clinical Microbiology 1998, 36:580-584.
33. Westermeyer J. The pro-heroin effects of anti-opium laws in Asia. Archives of General Psychiatry 1976, 33:1135-1139.
34. Wilson T.E., Sharma A., Zilmer K., Kalikova N., Uusküla A. The HIV prevention needs of injection drug users in Estonia. International Journal of STD & AIDS 2007, 18:389-391.